Year: 2016-17

Company: BD Biosciences

Liaison(s): Ramin Cyrus, Chuck Velnoskey

BD Life Sciences ( BD ) is a world leader in bringing innovative diagnostic and research tools to life scientists, clinical researchers, laboratory professionals, and clinicians involved in basic research, drug discovery and development, biopharmaceutical production, and disease management. BD’s Advanced Bioprocessing team is a cell solutions partner to leading biopharmaceutical companies in the process development and production of vaccines and biological drugs. In addition to the consulting and technological services it provides, BD also develops media and supplement products that have been used in the manufacturing of over 100 biopharmaceuticals. Recent mergers in the industry and subsequent vicissitudes of customers have led BD Biosciences to identify possible gaps and seek new opportunities that may enhance their portfolio and overall company strategy. The BD Team goals included identification of current unmet needs and pain points in the industry, with particular focus on mammalian cell culture, future disruptive manufacturing technologies ( perfusion bioreactors and HTST media treatment ), and key industry trends ( stem cell and whole cell therapy ). To achieve success, the team familiarized itself with current trends via in-depth review of recent market reports and interviews with key opinion leaders to understand the perspective and needs of influential experts. By evaluating media suppliers, contract manufacturing organizations, contract research organizations, emerging biopharma, and established biopharma companies, the team delivered actionable recommendations to BD supported by quantitative and qualitative data. The team provided solutions to current gaps in service and customer pain points that support BD’s mission to create solutions for the scientific community’s queries.